CD36 and neoplasm: We hypothesize that when patients with heterogeneous tumor cell expression of CD36/47 are treated with VT1021, tumor cells with high CD36 and CD47 would be killed, but tumor cells with low levels of CD36 and CD47 would not respond to the VT1021 treatment, resulting in a lack of response.